DCTH:NASDAQ
Delcath Systems Inc
၁၂.၂၄ US$
arrow_downward
-၀.၄၁%(-၀.၀၅၀) 1D
၁၂.၄၀ US$
arrow_upward
+၁.၃၁% (+၀.၁၆)bedtimeAfter hours
Closed: ဇွန် ၂၄, GMT-၄ ၁၆:၀၀:၀၁ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DCTH...
Open
၁၂.၃၆ US$
High
၁၂.၇၉ US$
Low
၁၂.၁၈ US$
Mkt. cap
၄၂.၂၅ ကုဋေ
Avg. vol.
၅.၅၀ သိန်း
Volume
၄.၆၉ သိန်း
P/E ratio
၂,၀၄၃.၄၁
52-wk high
၁၄.၁၈ US$
52-wk low
၈.၁၂ US$
EPS
၀.၀၁ US$
Beta
၀.၅၄
Shares outstanding
၃.၄၅ ကုဋေ
No. of employees
၁၅၆
Open
၁၂.၃၆ US$
High
၁၂.၇၉ US$
Low
၁၂.၁၈ US$
Mkt. cap
၄၂.၂၅ ကုဋေ
Avg. vol.
၅.၅၀ သိန်း
Volume
၄.၆၉ သိန်း
P/E ratio
၂,၀၄၃.၄၁
52-wk high
၁၄.၁၈ US$
52-wk low
၈.၁၂ US$
EPS
၀.၀၁ US$
Beta
၀.၅၄
Shares outstanding
၃.၄၅ ကုဋေ
No. of employees
၁၅၆
News stories
From sources across the web
Firstpost
·
ပြီးခဲ့သည့် ၃၀ မိနစ်
South Korean chipmaker SK Hynix jumps 11% as investors cheer $29 billion Nasdaq listing plan
NDTV Profit
·
ပြီးခဲ့သည့် ၃၃ မိနစ်
Wall Street Highlights: S&P 500, Nasdaq Give Back Gains as Chip-Stock Dip Buying Fades
MSN
·
ပြီးခဲ့သည့် ၂၁ မိနစ်
SK Hynix surges 11% after filing for blockbuster Nasdaq listing
Barron's
·
ပြီးခဲ့သည့် ၃ နာရီ
Verizon Just Got Kicked Out of the Dow, but Its 6% Dividend Yield Still Looks Solid
Profile
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
About Delcath Systems Inc
CEOGerard Michel
Employees၁၅၆
Founded၁၉၈၈
HeadquartersQueensbury, နယူးယောက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitedelcath.com
AI content may include mistakes. Learn more